Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital

Asparaginase treatment in infants with acute lymphoblastic leukemia; pharmacokinetics and asparaginase hypersensitivity in Interfant-06

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Response to: Patient-centred medical education: A proposed definition

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Associations between pretherapeutic body mass index, outcome, and cytogenetic abnormalities in pediatric acute myeloid leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Birgitte Klug Albertsen
  • Arja Harila-Saari
  • Kirsi Jahnukainen
  • Päivi Lähteenmäki
  • Pekka Riikonen
  • Merja Möttönen
  • Birgitte Lausen
Vis graf over relationer

Acute lymphoblastic leukemia (ALL) is a rare disease in infants. Asparaginase is an essential part of the treatment, and there Acute is a need to evaluate the efficiency and safety of this drug in this age group. We evaluated the pharmacokinetics of intramuscularly administered native E. coli asparaginase (Asparaginase Medac®) and PEG-asparaginase (Oncaspar®) as well as hypersensitivity reactions during treatment in Interfant-06 ( : NCT01025804). All patients without hypersensitivity had sufficiently high enzyme activity levels during treatment with both preparations. Patients with hypersensitivity reactions during treatment, characterized by the presence of either or not of clinical symptoms and no measurable enzyme activity, received ineffective therapy. For optimization of the bad prognosis in infant ALL, therapeutic drug monitoring should be performed for identification of patients who should be switched to a different asparaginase preparation because of inactivation of the drug.

TidsskriftLeukemia and Lymphoma
Udgave nummer6
Sider (fra-til)1469-1475
Antal sider7
StatusUdgivet - 2019

ID: 59087987